中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
19期
15-17
,共3页
糖尿病肾病%羟苯磺酸钙%白细胞介素-6%肿瘤坏死因子-α
糖尿病腎病%羥苯磺痠鈣%白細胞介素-6%腫瘤壞死因子-α
당뇨병신병%간분광산개%백세포개소-6%종류배사인자-α
Diabetic nephropathy%Dobesilate%Interleukin-6%Tumor necrosis factor-α
目的：探讨羟苯磺酸钙对早期糖尿病肾病患者血清白细胞介素-6（ IL-6）和肿瘤坏死因子-α（ TNF-α）的影响。方法将80例早期糖尿病肾病患者随机分为两组，观察组和对照组各40例，对照组采用降糖、降脂、血管紧张素转换酶抑制剂（ ACEI）或血管紧张素Ⅱ受体拮抗剂（ ARB）等药物治疗，观察组在以上治疗的基础上加用羟苯磺酸钙。两组共治疗12周。测定治疗前、治疗后4、8、12周的尿白蛋白排泄率（ UAER）。测定治疗前后患者血清的IL-6和TNF-α。结果治疗前两组患者 UAER比较差异无统计学意义（ P﹥0.05），治疗后8、12周，对照组UAER较治疗前明显降低（ P﹤0.05，P﹤0.01）；在治疗后4、8、12周，观察组比治疗前均有明显降低（ P﹤0.05，P﹤0.01），并且治疗后8、12周，观察组 UAER 均比对照组低（ P ﹤0.05）。两组治疗后血清 IL-6和 TNF-α均有明显降低，并且观察组治疗后血清 IL-6比对照组降低更明显（ P﹤0.05），观察组治疗后血清TNF-α比对照组降低也更明显（ P﹤0.01）。结论羟苯磺酸钙可以通过减轻早期糖尿病肾病患者的炎症反应而治疗疾病。
目的：探討羥苯磺痠鈣對早期糖尿病腎病患者血清白細胞介素-6（ IL-6）和腫瘤壞死因子-α（ TNF-α）的影響。方法將80例早期糖尿病腎病患者隨機分為兩組，觀察組和對照組各40例，對照組採用降糖、降脂、血管緊張素轉換酶抑製劑（ ACEI）或血管緊張素Ⅱ受體拮抗劑（ ARB）等藥物治療，觀察組在以上治療的基礎上加用羥苯磺痠鈣。兩組共治療12週。測定治療前、治療後4、8、12週的尿白蛋白排洩率（ UAER）。測定治療前後患者血清的IL-6和TNF-α。結果治療前兩組患者 UAER比較差異無統計學意義（ P﹥0.05），治療後8、12週，對照組UAER較治療前明顯降低（ P﹤0.05，P﹤0.01）；在治療後4、8、12週，觀察組比治療前均有明顯降低（ P﹤0.05，P﹤0.01），併且治療後8、12週，觀察組 UAER 均比對照組低（ P ﹤0.05）。兩組治療後血清 IL-6和 TNF-α均有明顯降低，併且觀察組治療後血清 IL-6比對照組降低更明顯（ P﹤0.05），觀察組治療後血清TNF-α比對照組降低也更明顯（ P﹤0.01）。結論羥苯磺痠鈣可以通過減輕早期糖尿病腎病患者的炎癥反應而治療疾病。
목적：탐토간분광산개대조기당뇨병신병환자혈청백세포개소-6（ IL-6）화종류배사인자-α（ TNF-α）적영향。방법장80례조기당뇨병신병환자수궤분위량조，관찰조화대조조각40례，대조조채용강당、강지、혈관긴장소전환매억제제（ ACEI）혹혈관긴장소Ⅱ수체길항제（ ARB）등약물치료，관찰조재이상치료적기출상가용간분광산개。량조공치료12주。측정치료전、치료후4、8、12주적뇨백단백배설솔（ UAER）。측정치료전후환자혈청적IL-6화TNF-α。결과치료전량조환자 UAER비교차이무통계학의의（ P﹥0.05），치료후8、12주，대조조UAER교치료전명현강저（ P﹤0.05，P﹤0.01）；재치료후4、8、12주，관찰조비치료전균유명현강저（ P﹤0.05，P﹤0.01），병차치료후8、12주，관찰조 UAER 균비대조조저（ P ﹤0.05）。량조치료후혈청 IL-6화 TNF-α균유명현강저，병차관찰조치료후혈청 IL-6비대조조강저경명현（ P﹤0.05），관찰조치료후혈청TNF-α비대조조강저야경명현（ P﹤0.01）。결론간분광산개가이통과감경조기당뇨병신병환자적염증반응이치료질병。
Objective To study the effect of dobesilate on serum interleukin-6( IL-6 )and tumor necrosis factor-α( TNF-α)in patients with early diabetic nephropathy. Methods Eighty patients with early diabetic nephropathy were randomly divided into two groups,the observation group( n=40 cases) and the control group( n=40 cases). The control group was treated with hypoglycemic,lipid-lowering, ACEI or ARB,while the observation group was treated with dobesilate based on the above therapy. They were all treated for 12 weeks. Urinary albumin excretion rate( UAER)was measured before and after 8 and 12 weeks of treatment. Serum IL-6 and TNF-α levels were detected before and after treatment. Re-sults There was no significant difference in UAER between the two groups before treatment( P ﹥0. 05 ). After 8 weeks and 12 weeks of treatment,UAER levels in the control group were significantly de-creased(P﹤0. 05,P﹤0. 01). After 4,8,12 weeks,UAER levels in the observation group were sig-nificantly lower than those before treatment(P﹤0. 05,P﹤0. 01). Eight and 12 weeks after treatment, UAER levels in the observation group were lower than those in the control group( P﹤0. 05 ). After treat-ment,serum levels of IL-6 and TNF-αwere significantly lower. Serum IL-6 level in the observation group decreased more significantly than that in the control group( P﹤0. 05 ). Serum TNF-αlevel in the obser-vation group decreased significantly than that in the control group( P﹤0. 01 ). Conclusions Dobesilate can reduce the early inflammatory response in patients with diabetic nephropathy and treat disease.
